EULAR 2026… EULAR 2026 Highlights – Spondyloarthritis (therapeutic) 22 Jul 202624 Jul 2026 Filgotinib significantly improves disease activity in patients with active axial spondyloarthritis: primary results from the phase 3 OLINGUITO trial Abstract format and assignment number: Oral presentation OP0234 Presenting author: X.…
EULAR 2025 highlights… EULAR 2025 Highlights – Spondyloarthritis: Clinical (therapeutic) 18 Jul 2025 Superior effectiveness and comparable drug retention of anti-TNF therapy versus anti-IL-17A in ankylosing spondylitis after first anti-TNF failure: A propensity score-matched analysis from the Czech ATTRA Registry Abstract format and…
ACR Highlights… ACR Convergence 2024 Highlights – Spondyloarthritis: Clinical (therapeutic) 19 Dec 202419 Dec 2024 Nonsteroidal Anti-Inflammatory Drug Use and Incident Hypertension Among Patients with Axial Spondyloarthritis Abstract format and assignment number: Poster 0540 Presenting author: J. Meade Aguilar (USA) Date: Saturday, 16th November 2024…
ACR Highlights… ACR Convergence Highlights 2023 – Spondyloarthritis II: Clinical (therapeutic) 9 Dec 20239 Dec 2023 Author: Bayram Farisogullari Kivitz et al. (0776) investigated the long-term efficacy, safety, and tolerability of intravenous (IV) secukinumab (SEC) in patients with active PsA through 52 weeks in a randomised,…